SenseToKnow Autism Screening Device Validation Study

Sponsor
Duke University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05874466
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH)
350
61

Study Details

Study Description

Brief Summary

This is a pivotal, prospective, double-blind, study to evaluate the sensitivity and specificity of the SenseToKnow app for the detection of autism spectrum disorder in children 16-36 months of age.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This is a pivotal, prospective, double-blind, study to evaluate the sensitivity and specificity of the SenseToKnow app for the classification of autism spectrum disorder when administered by parents in a sample of patients 16-36 months of age. The trial design is a non-interventional cross-sectional study comparing the SenseToKnow app classification of autism spectrum disorder ("autism") versus non-autism with the patient's diagnostic status based on expert clinical diagnosis in a population of pediatric patients.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    350 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    SenseToKnow STAR Study: A Study of Technologies for Assessing Children's Development
    Anticipated Study Start Date :
    Jul 1, 2023
    Anticipated Primary Completion Date :
    Aug 1, 2028
    Anticipated Study Completion Date :
    Aug 1, 2028

    Arms and Interventions

    Arm Intervention/Treatment
    Pediatric patients, 16-37 months of age, recruited through pediatric medical clinics

    Consecutive pediatric participants will be recruited and enrolled via > 6 participating sites comprised of pediatric medical clinics (e.g., primary care and family medicine clinics) that are part of the broader Duke University Health System (DUHS) located in North Carolina. Enrollment will proceed until the targets of N = 150 participants diagnosed with autism spectrum disorder and N = 200 without autism are reached.

    Outcome Measures

    Primary Outcome Measures

    1. Sensitivity of SenseToKnow for autism detection [Will be calculated based on data from Baseline/Timepoint 1]

      Sensitivity = #participants positive for autism on both SenseToKnow and expert clinical diagnosis / #participants positive for autism on both SenseToKnow and expert clinical diagnosis + #participants negative for autism on SenseToKnow who were positive for autism by expert clinical diagnosis

    2. Specificity of SenseToKnow for autism detection [Will be calculated based on data from Baseline/Timepoint 1]

      Specificity = #participants negative for autism on both SenseToKnow and expert clinical diagnosis / #participants negative for autism on both SenseToKnow and expert clinical diagnosis + #participants positive for autism on SenseToKnow who were negative for autism by expert clinical diagnosis

    Secondary Outcome Measures

    1. Positive Predictive Value of SenseToKnow (with and without adjustment for population prevalence) [Will be calculated based on data from Baseline/Timepoint 1]

      The likelihood that a participant with a positive test result has a diagnosis of autism.

    2. Negative Predictive Value of SenseToKnow (with and without adjustment for population prevalence) [Will be calculated based on data from Baseline/Timepoint 1]

      The likelihood that a participant with a negative test result does not have a diagnosis of autism

    3. Receiver Operating Characteristic Curve (ROC) and Area Under the Curve (AUC) with respect to the accuracy of the SenseToKnow app for autism versus non-autism classification [Will be calculated based on data from Baseline/Timepoint 1]

      ROC is a graphical plot that illustrates the diagnostic ability of a binary classifier system as its discrimination threshold is varied. AUC measures the area underneath the entire ROC curve.

    4. Sensitivity of SenseToKnow + Parent Survey for autism detection [Will be calculated based on data from Baseline/Timepoint 1]

      Sensitivity = #participants positive for autism on both SenseToKnow+Parent Survey and expert clinical diagnosis / # participants positive for autism on both SenseToKnow+Parent Survey and expert clinical diagnosis + #participants negative for autism on SenseToKnow+Parent Survey who were positive for autism by expert clinical diagnosis

    5. Specificity of SenseToKnow + Parent Survey Survey for autism detection [Will be calculated based on data from Baseline/Timepoint 1]

      Specificity = #participants negative for autism on both SenseToKnow+Parent Survey and expert clinical diagnosis / #participants negative for autism on both SenseToKnow+Parent Survey and expert clinical diagnosis + #participants positive for autism on SenseToKnow+Parent Survey who were negative for autism by expert clinical diagnosis

    6. Positive Predictive Value of SenseToKnow + Parent Survey (with and without adjustment for population prevalence) [Will be calculated based on data from Baseline/Timepoint 1]

      The likelihood that a participant with a positive test result has a diagnosis of autism.

    7. Negative Predictive Value of SenseToKnow + Parent Survey (with and without adjustment for population prevalence) [Will be calculated based on data from Baseline/Timepoint 1]

      The likelihood that a participant with a negative test result does not have a diagnosis of autism

    8. Receiver Operating Characteristic Curve (ROC) and Area Under the Curve (AUC) with respect to the accuracy of the SenseToKnow app + Parent Survey for autism versus non-autism classification [Will be calculated based on data from Baseline/Timepoint 1]

      ROC is a graphical plot that illustrates the diagnostic ability of a binary classifier system as its discrimination threshold is varied. AUC measures the area underneath the entire ROC curve.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Months to 36 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. Duke Health pediatric patient at enrollment

    2. 16-<37 months of age at enrollment

    3. Parent/legal guardian speaks English or Spanish

    4. Parent/legal guardian understands and voluntarily provides informed consent

    Exclusion Criteria:
    1. Severe motor impairment that precludes study measure completion

    2. Known genetic disorders

    3. Severe hearing or visual impairment as determined on physical examination

    4. Acute illnesses likely to prevent successful or valid data collection

    5. Uncontrolled epilepsy or seizure disorder

    6. History or presence of a clinically significant medical disease, or a mental state that could confound the study or be detrimental to the subject as determined by the investigator

    7. Acute exacerbations of chronic illnesses likely to prevent successful or valid data collection

    8. Receiving therapies that affect vision

    9. Parent/legal guardian and/or investigator believes that the child will be unable/unwilling to sit in the parent's lap to watch the app videos

    10. Parent/legal guardian indicates that they or their child is unwilling or unable to complete the app administration, surveys, or diagnostic assessment

    11. Participants who are otherwise judged as unable to comply with the protocol by the investigator

    12. Any other factor that the investigator feels would make the study measures invalid

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Duke University
    • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

    Investigators

    • Principal Investigator: Geraldine Dawson, PhD, Duke University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Duke University
    ClinicalTrials.gov Identifier:
    NCT05874466
    Other Study ID Numbers:
    • Pro00111371
    • 2P50HD093074
    First Posted:
    May 25, 2023
    Last Update Posted:
    May 25, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Duke University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 25, 2023